当前位置: X-MOL 学术Cancer Cell Int. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Mesenchymal stromal cells induce inhibitory effects on hepatocellular carcinoma through various signaling pathways.
Cancer Cell International ( IF 5.8 ) Pub Date : 2019-12-05 , DOI: 10.1186/s12935-019-1038-0
Jafar Ai 1 , Neda Ketabchi 2 , Javad Verdi 1 , Nematollah Gheibi 3 , Hossein Khadem Haghighian 4 , Maria Kavianpour 1, 5
Affiliation  

Hepatocellular carcinoma (HCC) is the most prevalent type of malignant liver disease worldwide. Molecular changes in HCC collectively contribute to Wnt/β-catenin, as a tumor proliferative signaling pathway, toll-like receptors (TLRs), nuclear factor-kappa B (NF-κB), as well as the c-Jun NH2-terminal kinase (JNK), predominant signaling pathways linked to the release of tumor-promoting cytokines. It should also be noted that the Hippo signaling pathway plays an important role in organ size control, particularly in promoting tumorigenesis and HCC development. Nowadays, mesenchymal stromal cells (MSCs)-based therapies have been the subject of in vitro, in vivo, and clinical studies for liver such as cirrhosis, liver failure, and HCC. At present, despite the importance of basic molecular pathways of malignancies, limited information has been obtained on this background. Therefore, it can be difficult to determine the true concept of interactions between MSCs and tumor cells. What is known, these cells could migrate toward tumor sites so apply effects via paracrine interaction on HCC cells. For example, one of the inhibitory effects of MSCs is the overexpression of dickkopf-related protein 1 (DKK-1) as an important antagonist of the Wnt signaling pathway. A growing body of research challenging the therapeutic roles of MSCs through the secretion of various trophic factors in HCC. This review illustrates the complex behavior of MSCs and precisely how their inhibitory signals interface with HCC tumor cells.

中文翻译:

间充质基质细胞通过各种信号途径诱导对肝细胞癌的抑制作用。

肝细胞癌(HCC)是全球最普遍的恶性肝病类型。HCC的分子变化共同导致Wnt /β-catenin成为肿瘤增殖信号通路,toll​​样受体(TLRs),核因子-κB(NF-κB)以及c-Jun NH2-末端激酶(JNK),主要的信号通路与促肿瘤细胞因子的释放有关。还应注意,Hippo信号通路在器官大小控制中起着重要作用,特别是在促进肿瘤发生和HCC发育中。如今,基于间充质基质细胞(MSC)的疗法已成为肝,肝衰竭和HCC等肝脏体外,体内和临床研究的主题。目前,尽管恶性肿瘤的基本分子途径很重要,在这种背景下获得的信息有限。因此,可能难以确定MSC与肿瘤细胞之间相互作用的真实概念。众所周知,这些细胞可向肿瘤部位迁移,因此可通过旁分泌相互作用在HCC细胞上发挥作用。例如,MSC的抑制作用之一是作为Wnt信号通路的重要拮抗剂的dickkopf相关蛋白1(DKK-1)的过表达。越来越多的研究通过在HCC中分泌各种营养因子来挑战MSC的治疗作用。这篇综述说明了MSC的复杂行为,以及它们的抑制信号如何与HCC肿瘤细胞相互作用。这些细胞可能迁移到肿瘤部位,因此通过旁分泌相互作用对HCC细胞产生作用。例如,MSC的抑制作用之一是作为Wnt信号通路的重要拮抗剂的dickkopf相关蛋白1(DKK-1)的过表达。越来越多的研究通过在HCC中分泌各种营养因子来挑战MSC的治疗作用。这项审查说明了MSC的复杂行为,并确切地说明了其抑制信号如何与HCC肿瘤细胞相互作用。这些细胞可能迁移到肿瘤部位,因此通过旁分泌相互作用对HCC细胞产生作用。例如,MSC的抑制作用之一是作为Wnt信号通路的重要拮抗剂的dickkopf相关蛋白1(DKK-1)的过表达。越来越多的研究通过在HCC中分泌各种营养因子来挑战MSC的治疗作用。这项审查说明了MSC的复杂行为,并确切地说明了其抑制信号如何与HCC肿瘤细胞相互作用。越来越多的研究通过在HCC中分泌各种营养因子来挑战MSC的治疗作用。这篇综述说明了MSC的复杂行为,以及它们的抑制信号如何与HCC肿瘤细胞相互作用。越来越多的研究通过在HCC中分泌各种营养因子来挑战MSC的治疗作用。这项审查说明了MSC的复杂行为,并确切地说明了其抑制信号如何与HCC肿瘤细胞相互作用。
更新日期:2019-12-05
down
wechat
bug